Trajectories of premalignancy during the journey from melanocyte to melanoma

Pathology. 2018 Jan;50(1):16-23. doi: 10.1016/j.pathol.2017.09.002. Epub 2017 Nov 10.

Abstract

A stepwise progression from melanocytic precursors to cutaneous melanoma is a well-established model, based on decades of careful observation and morphological analysis. The steps identified are benign melanocytic naevus, dysplastic naevus, 'radial growth phase' melanoma (including melanoma in situ) and 'vertical growth phase' melanoma (also termed tumourigenic melanoma). Recent genomic data have refined the understanding of the steps of melanoma development and their relationship to one another. These data support the existence of dysplastic naevi as distinct lesions; suggest the importance of clonal dynamics in the precursor steps of melanoma; and confirm the carcinogenic role of ultraviolet radiation throughout early melanoma development and progression. In this review, the steps of melanoma development and progression are summarised and discussed in the context of recent genomic studies. This new understanding of melanoma pathogenesis that has been facilitated through careful correlation of morphological and molecular features will allow the identification and development of robust biomarkers to assist in more accurate diagnosis and prognostication of melanocytic tumours.

Keywords: Melanoma; carcinogenesis; diagnosis; naevus; pathology; tumour progression.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Cell Transformation, Neoplastic / radiation effects*
  • Disease Progression
  • Dysplastic Nevus Syndrome / etiology*
  • Dysplastic Nevus Syndrome / genetics
  • Dysplastic Nevus Syndrome / pathology
  • Genomics*
  • Humans
  • Melanocytes / pathology
  • Melanocytes / radiation effects
  • Melanoma / etiology*
  • Melanoma / genetics
  • Melanoma / pathology
  • Melanoma, Cutaneous Malignant
  • Precancerous Conditions
  • Skin Neoplasms / etiology*
  • Skin Neoplasms / genetics
  • Skin Neoplasms / pathology
  • Ultraviolet Rays / adverse effects*

Substances

  • Biomarkers, Tumor